Preclinical models for antimicrobial compound efficacy in vivo assays
Actionable in vivo studies to dive into insightful data
In vivo preclinical models of bacterial infectious diseases
Vibiosphen proposes research into potential future therapies (new antibiotics, peptides, biologics, immune modulator, phages, …..) against gram-negative or gram-positive bacteria to treat respiratory tract infections, septicemia, urinary tract infections, gastro-intestinal and skin infections.
Vibiosphen offers customized study designs to accurately address the problematic its partner faces.
- Mouse monitoring (survival, body weight, clinical symptoms)
- Bacterial loads in organs of interest (CFU, qPCR)
- Host response (biomarkers of inflammation and immunity)
- Histopathological analysis
- Mouse monitoring (survival, body weight, clinical symptoms)
- Viral loads (PFU, qPCR, TCID50)
- Host response (biomarkers of inflammation and immunity)
- Histopathological analysis
In vivo preclinical models of viral infectious diseases
Vibiosphen has a high level of expertise in producing predictive pharmacological models of viral infections caused by influenza H1N1 and Sars-CoV-2.
Vibiosphen proposes research into potential future therapies to treat respiratory tract infections, as an example.
Vibiosphen offers customized study designs to accurately address the problematic its partner faces.
In vivo preclinical models of fungal infectious diseases
Our preclinical mouse models have been optimized to assess drug efficacy in pneumonia, septicemia, skin and vaginal infections.
Vibiosphen offers customized study designs to accurately address the problematic its partner faces.
- Mouse monitoring (survival, body weight, clinical symptoms)
- Bacterial loads in organs of interest (CFU, qPCR)
- Host response (biomarkers of inflammation and immunity)
- Histopathological analysis